October 4, 2021 -- Halo Labs has launched Aura GT, a next-generation instrument that can correlate capsid aggregation with DNA leakage or empty and full capsids.
Aura GT definitively identifies capsid from noncapsid aggregates during gene therapy product development. Image courtesy of Halo Labs.
Aura GT uses background membrane imaging and fluorescent membrane microscopy to differentiate aggregated capsids from contaminants and carrier proteins that could harm patients, the company said. It can also identify DNA leaks in gene therapy products so researchers can pinpoint and correct the mechanism of aggregation.
This is the second product launch related to the cell and gene therapy space for Halo Labs in 2021. Earlier this year, the company released Aura CL, an instrument to measure cell therapy product quality.
Copyright © 2021 scienceboard.net